<i>Mycobacterium bovis</i>bacille Calmette–Guérin strains secreting listeriolysin of<i>Listeria monocytogenes</i>

Hess, Jürgen; Miko, Diana; Catic, André; Lehmensiek, Vera; Russell, David G.; Kaufmann, Stefan H. E.

doi:10.1073/pnas.95.9.5299

Cited by 175 publications

(133 citation statements)

References 37 publications

(33 reference statements)

Supporting

Mentioning

127

Contrasting

Unclassified

Order By: Relevance

“…These findings highlight the possibility that pro-apoptotic vaccines may generate a better CD8 + T cell response. It should be noted, however, that it has not yet been addressed whether the increased protection afforded by the engineered BCG is due to an increased CD8 + T cell response, it's proposed mechanism of action [50,51].…”

Section: Intracellular Bacteriamentioning

confidence: 99%

Next generation: tuberculosis vaccines that elicit protective CD8⁺T cells

Behar

Woodworth

2007

Expert Review of Vaccines

View full text Add to dashboard Cite

SummaryTuberculosis continues to cause considerable human morbidity and mortality across the world, particularly in people coinfected with HIV. The emergence of multidrug resistance makes the medical treatment of tuberculosis even more difficult. Thus, the development of a tuberculosis vaccine is a global health priority. Here we review the data concerning the role of CD8 + T cells in immunity to tuberculosis and consider how CD8 + T cells can be elicited by vaccination. Many immunization strategies have the potential to elicit CD8 + T cells, and we critically review the data supporting a role for vaccine-induced CD8 + T cells in protective immunity. The synergy between CD4 + and CD8 + T cells suggests that a vaccine which elicits both T cell subsets has the best chance at preventing tuberculosis.

show abstract

Section: Intracellular Bacteriamentioning

confidence: 99%

Next generation: tuberculosis vaccines that elicit protective CD8⁺T cells

Behar

Woodworth

2007

Expert Review of Vaccines

View full text Add to dashboard Cite

show abstract

“…the phagosomes membrane; ii) it cannot block early acidification of phagosomes as a result of the urease gene deletion (ureC) [38,39]. As a consequence, rBCG ureC:hly + can translocate to the cytoplasm of infected dendritic cells, where antigens can be readily presented through the MHC-I pathway.…”

Section: Recombinant Bcgmentioning

confidence: 99%

The quest for a new vaccine against tuberculosis

Delogu

Fadda

2009

J Infect Dev Ctries

View full text Add to dashboard Cite

Tuberculosis (TB) is still one of the deadliest human diseases, killing 1,6 million people each year, mostly in developing countries. The vaccine currently used, Bacille Calmette and Guerin (BCG), is effective in preventing the most severe disseminated forms of disease in children and newborns, but its efficacy against active TB in adults has been challenged by several clinical studies. It is a common opinion that only the development of a new and more effective vaccine against TB would significantly ease the pandemic. In the last few years, the search for a new vaccine has gained a new momentum. New live and attenuated strains of M. tuberculosis, improved recombinant BCG strains and subunit vaccines have been tested in preclinical animal models, and some of them showed promising results. Unfortunately, the lack of immunological correlates of protection makes very difficult to anticipate or foresee the efficacy of any of these new vaccines and only phase III clinical trials, that are expected to start in 2009 and last few years, will tell us the real value of these new prophylactic tools. This review highlights the different strategies that are being implemented for the development of an improved vaccine against TB, the rationale behind them and the potential and feasible vaccination schedules that could be implemented.

show abstract

“…Almost all such studies have involved testing purified or recombinant antigens in mouse models of tuberculosis, in a variety of adjuvants, or expressed in Vaccinia or Salmonella [201]. Others have modified BCG in the hope of increasing its immunogenicity and its ability to induce a CD8 z cells response [52]. It has become clear that the usefulness of this approach is limited.…”

Section: Attempts To Identify Protective Antigens Using Animal Studiesmentioning

confidence: 99%

“…In an in vitro system, this ability to activate CD8 z cells seemed to involve causing leakiness of the phagosome so that antigens reach the cytoplasm and hence join the conventional pathway for presentation on MHC Class 1 [48,49], though another novel pathway may also be involved [50]. A haemolysin-like molecule is in fact expressed by both M. tuberculosis and BCG [51], and a BCG strain expressing the haemolysin from Listeria monocytogenes has been developed in the belief that this will increase the CD8 z response [52].…”

Section: The T Cell Types Involved In Immunitymentioning

confidence: 99%

M. tuberculosis: immunology and vaccination

2001

View full text Add to dashboard Cite

Tuberculosis is increasing. Current treatment regimens require at least 6 months, because latent or stationary phase organisms are difficult to kill. Such regimens do not achieve full compliance, and "directly observed therapy short course" (DOTS) is having less impact than expected. This worrying situation is aggravated by coinfection with human immunodeficiency virus (HIV), and by the increase in drug-resistant strains.We need new insights that lead to more rapid therapies and immunotherapies, and more reliable vaccines.Recent insights have come from: understanding of the relationship between Mycobacterium tuberculosis and macrophages; the multiple T cell types that recognise mycobacterial peptides, lipids and glycolipids; the critical role of interferon-c (IFNc) and interleukin-12 (IL-12) in human mycobacterial infection revealed by genetically defective children; quantitation of the presence and importance of Th2 lymphocyte activation in human tuberculosis; the role of local conversion of inactive cortisone to active cortisol in the lesions; the recognition that some effective prophylactic vaccines also work as immumotherapeutics whereas others do not. In the longer term the recent sequencing of the M. tuberculosis genome will lead to further advances.In the short term, effective immunotherapy remains the most accessible breakthrough in the management of tuberculosis. The types of practical advance that will result from sequencing the genome are discussed speculatively, but cannot yet be predicted with certainty.

show abstract

Mycobacterium bovisbacille Calmette–Guérin strains secreting listeriolysin ofListeria monocytogenes

Cited by 175 publications

References 37 publications

Next generation: tuberculosis vaccines that elicit protective CD8⁺T cells

Next generation: tuberculosis vaccines that elicit protective CD8⁺T cells

The quest for a new vaccine against tuberculosis

M. tuberculosis: immunology and vaccination

Contact Info

Product

Resources

About

Mycobacterium bovisbacille Calmette–Guérin strains secreting listeriolysin ofListeria monocytogenes

Cited by 175 publications

References 37 publications

Next generation: tuberculosis vaccines that elicit protective CD8+T cells

Next generation: tuberculosis vaccines that elicit protective CD8+T cells

The quest for a new vaccine against tuberculosis

M. tuberculosis: immunology and vaccination

Contact Info

Product

Resources

About

Next generation: tuberculosis vaccines that elicit protective CD8⁺T cells

Next generation: tuberculosis vaccines that elicit protective CD8⁺T cells